ARS Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

ARS Pharmaceuticals

21/03/2024 21:12

* ARS Pharmaceuticals Inc  SPRY.OQ  reported a quarterly
adjusted
loss of 7 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of 77 cents.  The mean expectation of three analysts for the
quarter was for a loss of 14 cents per share. Wall Street
expected results to range from -17 cents to -11 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ARS Pharmaceuticals Inc's reported EPS for the quarter was
a
loss of 7 cents​.
    * The company reported a quarterly loss of $7.17 million.
    * ARS Pharmaceuticals Inc shares had risen by 58.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for ARS
Pharmaceuticals Inc is $18.50 
This summary was machine generated from LSEG data March 21 at
09:11 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.14          -0.07          Beat
 Sep. 30 2023      -0.18          -0.16          Beat
 Jun. 30 2023      -0.17          -0.18          Missed
 Mar. 31 2023      -0.17          -0.16          Beat